NCT04645485View on ClinicalTrials.gov

Safety and Tolerability of Autologous Non-hematopoietic Peripheral Blood Stem Cells Therapy in Healthy Adult Volunteers.

PHASE1CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

May 12, 2020

Primary Completion Date

June 30, 2020

Study Completion Date

July 30, 2020

Conditions
Healthy
Interventions
BIOLOGICAL

Nebulization of autologous non-hematopoietic peripheral blood stem cells (NHPBSC).

Participants received the investigational therapy through compressor (jet) nebulization, in two doses divided on Days 0 and 1. Each dose contains 10 mL of peripheral blood-derived stem cells CD45-/CD90+/CD133+.

Trial Locations (1)

4600

Abu Dhabi Stem Cells Center, Abu Dhabi

All Listed Sponsors
lead

Abu Dhabi Stem Cells Center

OTHER_GOV

NCT04645485 - Safety and Tolerability of Autologous Non-hematopoietic Peripheral Blood Stem Cells Therapy in Healthy Adult Volunteers. | Biotech Hunter | Biotech Hunter